# OnCo record prostate-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/prostate-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "prostate-cancer-signalling" ;
  schema:name "Prostate cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05215"@en, "Prostate cancer"@en ;
  schema:description "KEGG's prostate cancer map centres on the androgen receptor, the hormone switch that prostate cells depend on, plus loss of PTEN and NKX3.1 that lets PI3K/AKT growth signalling run free. Hormone therapy, AR antagonists and now AKT inhibitors act on these two arms."@en ;
  schema:url <https://onco.cc/pathways/prostate-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05215>, <https://doi.org/10.1038/nrc4016> ;
  onco:related <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/mdm2/>, <https://onco.cc/targets/psma/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/apalutamide/>, <https://onco.cc/drugs/darolutamide/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/talazoparib/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/> .